On August 13, 2026, the US Food and Drug Administration (FDA) granted a citizen petition submitted by Scott Olitsky, MD, MBA, Cure HHT’s Global Center of Excellence and Outreach Director, calling for stronger safety warnings for ferric carboxymaltose, commonly known by the brand name Injectafer and Ferinject

As a result, the FDA has approved a new boxed warning—sometimes called a “black box warning”—about the risk of hypophosphatemia, or dangerously low phosphate levels in the blood, and the serious complications that can sometimes follow.

For people living with HHT, this issue hits especially close to home.

Chronic nosebleeds and gastrointestinal bleeding make iron deficiency and iron-deficiency anemia a reality for many people in our community. Many require IV iron supplementation not just once, but repeatedly over months or years. That makes understanding the safety profile of the iron products used in HHT care incredibly important.

Turning an HHT Concern Into Action

Dr. Olitsky’s petition asked the FDA to strengthen warnings around FCM because of its association with hypophosphatemia and the potential consequences of severe or prolonged phosphate depletion.

For some people, low phosphate may be temporary. For others, it can become severe or persist over time, contributing to muscle weakness, bone pain, difficulty walking, osteomalacia, fractures and, in serious cases, potentially life-threatening complications.

There is another challenge for people with HHT: symptoms like fatigue and weakness can look a lot like the symptoms of iron deficiency itself. That can make low phosphate harder to recognize without appropriate monitoring.

The FDA had already strengthened Injectafer’s safety information in previous years. But after reviewing new evidence—including adverse-event reports, published research and real-world laboratory data—the Agency determined that stronger action was needed.

Its review identified 134 reports and published cases of serious, symptomatic hypophosphatemia associated with ferric carboxymaltose between July 1, 2022 and June 30, 2025. Some of those cases were severe, prolonged, difficult to treat or associated with serious outcomes.

The FDA also found that phosphate testing was happening far less often than expected, even though previous prescribing information already recommended monitoring for certain patients at increased risk.

Together, that evidence led the FDA to grant Dr. Olitsky’s petition.

For our community, this is more than a labeling change. It is a powerful example of what can happen when someone who understands the realities of HHT care recognizes a problem, follows the evidence and keeps pushing for safer care.

“Dr. Olitsky saw something that mattered for people with HHT and refused to let it be overlooked. His leadership on this petition shows exactly why HHT expertise is so important—not only for our own community, but for every patient who may benefit from safer, better-informed care. We are incredibly grateful for his persistence and commitment to patients.”
— Marianne Clancy, CEO, Cure HHT

Summary for Healthcare Professionals

For clinicians caring for people with HHT, the key change is that Injectafer (ferric carboxymaltose) now carries a boxed warning for hypophosphatemia, with stronger guidance around phosphate monitoring. The updated labeling recommends checking serum phosphate in patients at risk for low phosphate and in any patient receiving a repeat course of Injectafer within three months. It also clarifies that symptomatic hypophosphatemia has occurred after both single and multiple doses, including in patients without apparent risk factors. Patients who develop severe symptomatic or persistent hypophosphatemia should permanently discontinue Injectafer.

This is especially relevant in HHT, where chronic blood loss can mean repeated IV iron treatment over many years. When selecting an IV iron formulation, clinicians should consider not only how effectively it replaces iron, but also the potential risks associated with repeated exposure. Symptoms such as fatigue and weakness may also overlap with iron-deficiency anemia, making appropriate monitoring and early recognition particularly important.

Read more on the Cure HHT Research Network.

Please note: The Hub is only intended for professionals in the medical and/or scientific community and closed to patients and caregivers. If you haven’t joined the Hub yet, you will be prompted to create an account.

Summary for Patients, Caregivers, and the General Public

If you receive Injectafer for iron deficiency or anemia, the new boxed warning does not mean you should stop treatment. It means the FDA is making the risk of low phosphate more visible so patients and healthcare professionals can make informed decisions and monitor when needed. Low phosphate can sometimes cause symptoms such as muscle weakness, bone pain or difficulty walking, and severe or long-lasting cases can lead to more serious complications.

For people with HHT—especially those who receive IV iron repeatedly—it is worth knowing which type of IV iron you receive and talking with your care team about whether phosphate testing is appropriate for you. Because symptoms like fatigue and weakness can look similar to iron deficiency itself, be sure to tell your healthcare provider about new or worsening symptoms after an infusion. Do not stop or change your iron treatment without speaking with your care team.

Looking for additional information? Access our previously published FAQ about these changes.

The post FDA Adds Boxed Warning to Ferric Carboxymaltose Following Petition Led by Cure HHT’s Dr. Scott Olitsky appeared first on CureHHT.

The Palmer Family Fund awards help promising young investigators from around the world attend the conference, share their findings and build relationships with established leaders in hereditary hemorrhagic telangiectasia research and care.

The 2026 award recipients are:

• Andrej Shoykhet, Leiden University Medical Center — Netherlands

Non-invasive Functional Ultrasound Imaging Identifies Vascular Alterations Following Endothelial SMAD4 Depletion

• Anirban Ray, Tulane University — United States

Endothelial FOXO1 Modulation Attenuates Pathological Angiogenesis in Endoglin-Deficient HHT Mice

• Elaine Kim, University of California, San Francisco — United States

Sex-Based Disparities in the Diagnosis of Hereditary Hemorrhagic Telangiectasia: A Retrospective Analysis

• Eleanor Steiner, University of North Carolina — United States

Pulmonary AVM Recanalization Rates in Pediatric HHT

• Elisavet Koutala, Leiden University Medical Center — Netherlands

Assessing ALK1-BMPR2 Bispecific Antibody Agonist Therapy in HHT Mice Using Super-Resolution Ultrasound Imaging

• Finn Timmermans, Leiden University Medical Center — Netherlands

Endothelial SMAD1/5 Deficiency Causes Early Pericyte Dysfunction and Neurovascular Uncoupling without Vascular Dilation Relevant to Hereditary Hemorrhagic Telangiectasia

• Jan Pieter van Veen, St. Antonius Hospital, Nieuwegein — Netherlands

Grade of Pulmonary Right-To-Left Shunting on TTCE: Confirmation of Risk of Cerebral Complications?

• Joline Michiels, KU Leuven — Belgium

Staphylococcus Aureus Infections in Patients with Hereditary Hemorrhagic Telangiectasia: A Retrospective Cohort Study

• Ons Mamai, University of California, San Francisco — United States

PTPN14 Stabilizes Nuclear SMAD4 To Maintain Arterial Endothelial Cell Identity and Suppress Arteriovenous Malformations

• Sartaaj Walia, University of California, San Francisco — United States

Comparison of Ferumoxytol-Enhanced MRI with Gadolinium-Enhanced MRI For the Detection of Brain Arteriovenous Malformations: Initial Results

• Yue Qi, Stanford University — United States

Identification of Modifier Genes Contributing to Pulmonary Arterial Hypertension in Hereditary Hemorrhagic Telangiectasia Patients

In addition to the Palmer Family Fund award recipients, 31 additional travel grants were made possible through the generous support of the Grace Nolan Foundation, Cure HHT and, for the first time, Cure HHT Canada. Together, these investments will help 46 investigators overcome the financial barriers that can prevent early-career researchers from attending international scientific meetings and presenting their work to the broader HHT community.

“The breadth of topics represented by this year’s applicants is incredibly encouraging, and so is the growing number of talented young investigators choosing to devote their work to HHT,” said Marianne Clancy, Chief Executive Officer of Cure HHT. “Their interest reflects the momentum building across this field and gives us tremendous confidence in the future of HHT research and care. We are excited to welcome them to Cape Cod this fall, hear about their work and help connect them with the global experts and collaborators who can carry these ideas forward.”

Cure HHT’s HHT International Scientific Conference is the largest global gathering dedicated exclusively to advancing the understanding, diagnosis, and treatment of HHT. Held every two years, the conference creates a collaborative environment where emerging research can be shared, challenged and translated into meaningful progress for patients and families.

Supporting young investigators is central to the conference’s long-term impact. By helping early-career scientists and clinicians enter the HHT field, present new ideas and establish international collaborations, these travel awards strengthen the pipeline of experts working toward better treatments and, ultimately, a cure.

The post Cure HHT Announces Palmer Family Fund Young Investigator Travel Award Recipients for 16th HHT International Scientific Conference appeared first on CureHHT.

The post Your Samples, Your Impact: How the Cure HHT Biobank is Accelerating Research appeared first on CureHHT.

We are also pleased to welcome Vaderis as a Cure HHT Clinical Trial Network partner alongside Diagonal Therapeutics and Atavistik Bio—a meaningful step in our shared commitment to advancing research that reflects the urgent needs of the HHT community.

“This announcement marks more than progress for one study—it reflects the momentum Cure HHT has worked urgently and intentionally to build for the entire HHT community,” said Marianne Clancy, Chief Executive Officer of Cure HHT. “Vaderis is now the third partner to join the Cure HHT Clinical Trial Network, signaling a profound shift in what is possible for patients and their families. This initiative is helping move emerging science from pipeline to purpose, accelerating the hope of not one, but multiple treatment options that may become available within this lifetime, across the globe.”

The post Vaderis Therapeutics Announces Series B Financing and Initiation of the Global Phase 3 HEROIC Study appeared first on CureHHT.

This partnership reflects exactly why the Clinical Trial Network was created: to connect promising research with experienced HHT clinicians, trial-ready Centers of Excellence, and the patients and families who make progress possible. Together, Cure HHT and Atavistik will work to expand global interest in the Harmony-HHT study and help eligible individuals learn more about opportunities to participate.

“We are thrilled to welcome Atavistik Bio to the Cure HHT Clinical Trial Network and to support the advancement of the Harmony-HHT study,” said Marianne Clancy, Chief Executive Officer of Cure HHT. “Our community has waited far too long for therapies developed specifically for HHT, and every new clinical program brings renewed reason for hope. By connecting Atavistik with our global network of patients, clinicians, and Centers of Excellence, we can help ensure the HHT community is informed, engaged, and meaningfully represented as this important work moves forward.”

The post Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for HHT appeared first on CureHHT.

Cure HHT is the official patient advocacy partner aligned with this effort and is helping build awareness and interest across the global HHT community. Diagonal Therapeutics is also a partner in the Cure HHT Clinical Trial Network, making this the first clinical trial announcement to emerge from the network.

“This announcement belongs not only to the researchers and partners advancing this work, but also to the people affected by HHT who make progress possible,” said Marianne Clancy, Chief Executive Officer of Cure HHT. “Participating in an early-stage clinical trial requires tremendous courage, hope, time, and personal commitment. We are profoundly grateful to every individual and family who chooses to contribute to the development of new treatments—not only for themselves, but for the entire global HHT community and for generations still to come.”

Interested in the Study?

The DIAMOND trial is currently enrolling at clinical sites in Australia and New Zealand, but additional locations are expected to open around the world. Help Diagonal Therapeutics understand where interest is strongest—and where future trial sites could have the greatest impact—by completing Cure HHT’s clinical trial interest form.

The post Diagonal Therapeutics Announces First Patient Dosed In Phase 1/2 Diamond Clinical Trial Of Diag723 For HHT appeared first on CureHHT.

For years, they had been searching for answers. Ella had muscle weakness and hypotonia, and her family wanted to understand why certain things seemed harder for her. They pursued genetic testing hoping it would help explain one part of Ella’s story.

Instead, the results revealed something they had not been looking for at all.

Hereditary Hemorrhagic Telangiectasia. HHT.

In an instant, her family was pulled into the world so many rare disease families know too well: new specialists, new appointments, new testing, new questions, and a diagnosis that seemed to arrive with more uncertainty than answers.

What did this mean for Ella’s future? What would her care look like? What else did they need to know? What had they missed simply because no one knew to look for HHT?

It was overwhelming. It was scary. And it was a lot for any family to carry. However, through every appointment, every procedure, every test, and every diagnosis, Ella has continued to be Ella.

She smiles. She plays. She learns. She lights up the rooms she enters. She faces challenges with a kind of bravery that has become a daily source of strength for everyone who loves her. That is why her family calls themselves, Team Ella.

For Jelina’s family, that team has included Ella’s pediatrician and the care team at Nicklaus Children’s Hospital. It has included geneticists who took the time to personally call Ella’s pediatrician, explain the diagnosis, and help build a plan for her care.

Ella’s story is also a reminder of how many families are still searching for answers. How many people may be living with HHT without knowing it. How many diagnoses may be missed, delayed, or discovered only by chance.

Earlier diagnosis can save lives. Education can help families find answers sooner. And sharing stories like Ella’s can help another parent, another patient, another family recognize the signs and seek the care they need.

If Ella’s story moved you, please consider making a gift to the Visible Together campaign today. Your support helps Cure HHT advance the research, education, advocacy, and patient support that families like Ella’s are counting on.

This HHT Awareness Month, we are Visible Together because visibility changes what is possible.

Your gift to Cure HHT helps support the education, advocacy, research, and expert care that move this community forward. It helps more providers understand HHT. It helps more patients find answers. It helps build a future where rare disease care is not defined by isolation, but by connection, knowledge, and hope. Thanks to a generous group of donors, a significant portion of gifts made during HHT Awareness Month will be matched.

The post Visible Together: The Strength of Team Ella appeared first on CureHHT.

It was present in the kitchen, where her father stood over the sink with severe nosebleeds, bleeding into a red Solo cup. It was hiding in her family’s medical history, even though no one fully understood yet. It was like an ominous cloud—quiet, familiar, and deeply influential in all aspects of life.

Kelsey was diagnosed with hereditary hemorrhagic telangiectasia, or HHT, when she was 11 years old.

“Thank goodness the pieces were put together,” she says.

That diagnosis mattered. Not because it made HHT easier, but because it gave her family a way to understand what had been happening—and what could happen next.

For Kelsey, HHT did not follow the version of the disease that many people expect. Her nosebleeds were relatively mild. But HHT is not just nosebleeds. It is a complex, multi-system genetic disease that can affect the blood vessels in the lungs, brain, liver, gastrointestinal tract, and beyond.

Kelsey’s HHT mutation contributed to pulmonary arterial hypertension (PAH), a serious condition involving high blood pressure in the arteries between the heart and lungs. She also developed microscopic gastrointestinal bleeding, which worsened as her PAH worsened. Over time, anemia became one of her most serious complications—not because of nosebleeds, but because of bleeding that was much harder to see.

The two diseases fed into one another. Each made the other worse.

Eventually, Kelsey needed a double lung transplant.

This is what invisibility can cost someone.

HHT is often minimized because its most recognizable symptom—nosebleeds—can seem ordinary from the outside. But recurrent, unexplained nosebleeds are not something to dismiss. And for many patients, the most dangerous complications are not visible at all until they have already caused serious harm.

Kelsey understands this personally. She also sees it professionally, in her work with HHT patients.

She hears it in the voices of people who call for help after being dismissed. She hears it from patients whose symptoms were minimized, whose complications snowballed, whose care might have looked very different if someone had recognized HHT earlier.

“It’s in the worried tears and shaky voices of patients talking to me on the phone asking for help,” she says. “It’s truly heartbreaking. It doesn’t impact just the affected person; it affects a whole circle.”

That circle includes parents, children, siblings, spouses, caregivers, clinicians, researchers, and every person who has sat beside someone they love, waiting for answers that should have come sooner.

For Kelsey, Visible Together means changing that.

It means HHT patients being loud and proud about their diagnosis. It means providers, researchers, caregivers, and families talking openly about the challenges of this disease. It means education, research, and advocacy working together—because no one part is enough on its own.

HHT requires coordinated, specialized care because it does not stay neatly in one lane. One organ system can affect another. Symptoms that seem separate may be connected. Patients need multidisciplinary teams who understand the nuances of this disease and can work together to prevent complications, not just respond to them.

“The goal is mitigating the effects of HHT,” Kelsey says, “and the hope is to cure it.”

That hope is why visibility matters.

Your support of the Visible Together campaign helps Cure HHT continue the work that changes lives: educating families and future practitioners, expanding awareness, supporting expert care, and advancing research toward better treatments and, one day, a cure.

Kelsey wants donors to know that HHT may already affect someone they know—even if they do not know it yet.

That is why this campaign matters.

When HHT becomes visible, patients are believed sooner. Families are screened earlier. Clinicians know what to look for. Research moves forward. Lives can change.

Today, on Global HHT Awareness Month, we can make sure fewer people live under an unnamed cloud.

Together, we can make HHT visible.

This HHT Awareness Month, we are Visible Together because visibility changes what is possible.

Your gift to Cure HHT helps support the education, advocacy, research, and expert care that move this community forward. It helps more providers understand HHT. It helps more patients find answers. It helps build a future where rare disease care is not defined by isolation, but by connection, knowledge, and hope. Thanks to a generous group of donors, a significant portion of gifts made during HHT Awareness Month will be matched.

The post Visible Together: Kelsey’s Story appeared first on CureHHT.

They came after she jumped into a swimming pool. They came after a hot shower. They came often enough to be noticed, but not seriously enough to be investigated.

Doctors told her it was just something she would have to live with.

So she did.

Erin grew up active and athletic. For years, the nosebleeds were the only visible sign that something deeper was happening inside her body. There were no clear warnings. No urgent referrals. No one saying the words hereditary hemorrhagic telangiectasia, or HHT.

Then Erin became pregnant, and the bleeding changed.

She remembered standing over the sink as blood poured from her nose. What had once been brushed off as an inconvenience became frightening, severe, and impossible to ignore. An ENT cauterized her nose, but the treatment did not solve the problem.

It was not until Erin was 40 years old that another ENT examined her and recognized what had been missed for decades.

“You have HHT.”

With those words, Erin’s life shifted. One diagnosis opened the door to genetic testing, MRIs, CT scans, surgeries, and a new understanding of all those years of unexplained bleeding. Doctors found three large arteriovenous malformations (AVMs) in her lungs. Looking back, Erin realized how fortunate she had been to get through two pregnancies safely without knowing the risks she carried.

But HHT did not stop with Erin.

Because HHT is genetic, Erin had both of her children tested. Her son, Bryan, also has HHT. After some time, her mother, Deidre, was tested too. She received her diagnosis at age 70.

Three generations. One condition. Decades of missed signs.

Today, HHT is part of Erin’s daily life not only as a patient, but as a mother and daughter. She describes herself as a case manager for both herself and Bryan, making sure follow-up appointments, scans, bloodwork, ENT care, respirology visits, and ongoing monitoring do not fall through the cracks.

That is one of the quieter burdens of HHT. It is not only the bleeding. It is the planning. The tracking. The waiting. The worry that something serious may be growing unseen.

Erin and Bryan both experience periods of anemia and require iron infusions. When anemia hits, everyday tasks can become exhausting. The ordinary rhythms of life—work, school, family, errands, meals, rest—become heavier.

For Bryan, more treatment is ahead. Soon, he will need nose ablation and lung embolization. Erin worries about his untreated lung AVMs. She worries about whether new lung AVMs could develop for her. She worries about the possibility of a blood clot traveling to the brain or lungs. She worries about the cumulative effects of CT scans, about a major medical event, about what HHT could mean for her lifespan and for her son’s future.

And she worries about her mother.

Deidre has large AVMs on her tongue that bleed heavily when she eats hot or spicy food. She also has a visible AVM growing on her face, something that can bring embarrassment on top of fear. Heavy bleeds from her nose or tongue are not just physically difficult. They are emotionally draining.

That is what so many people misunderstand about HHT. It is more than “just a nosebleed.”

HHT can affect the lungs, brain, liver, skin, tongue, and other parts of the body. It can be life-threatening if left untreated. And because it often hides behind symptoms that are minimized or misunderstood, diagnosis can come far too late.

For Erin, visibility matters because she knows what it means to go unseen.

She knows what it means to spend years being told to live with a symptom that deserved answers. She knows what it means to discover, only later, that her body had been carrying risks no one had named. She knows what it means to look at her son and wish that his path could be clearer, safer, and better supported than her own.

This Global HHT Awareness Day, Erin’s story is a reminder of why we come together.

For the children who deserve answers before crisis. For the parents carrying worry they cannot set down. For the grandparents who spent a lifetime without a name for what they were experiencing.

We are visible together because an earlier diagnosis can save lives.

Your gift to Cure HHT during HHT Awareness Month helps fuel the awareness, education, research, and care that families like Erin’s need. It helps bring HHT out of the shadows. It helps more people recognize the signs, ask the right questions, and find expert care sooner.

For Erin, Bryan, Deidre, and every family still waiting for answers, visibility can change everything.

Please make a gift today and help us build a future where no one has to live for decades with HHT unseen.

This HHT Awareness Month, we are Visible Together because visibility changes what is possible.

Your gift to Cure HHT helps support the education, advocacy, research, and expert care that move this community forward. It helps more providers understand HHT. It helps more patients find answers. It helps build a future where rare disease care is not defined by isolation, but by connection, knowledge, and hope. Thanks to a generous group of donors, a significant portion of gifts made during HHT Awareness Month will be matched.

The post Visible Together: Three Generations of HHT appeared first on CureHHT.

He was the unexpected joy who entered Jenn Doughty’s life when she learned she was pregnant at 15 weeks. He was happy, giggly, full of energy, and just the right amount of mischievous. He brought laughter into their home in the way only a child can—loudly, completely, and without warning.

At four years old, Barrett was all personality. He was silly and bright and full of life.

Then, one ordinary morning, everything changed.

Jenn’s husband was preparing to leave for a four-day flight assignment. Jenn was getting ready for a business trip to Washington, DC. It was the kind of busy family morning so many of us know well—bags being packed, schedules being checked, everyone trying to get out the door.

Barrett wandered into Jenn’s bathroom while she was getting ready.

“Mommy, I feel so silly today!” he said, wiggling around.

Jenn laughed. It felt like a normal moment. A sweet, funny, very Barrett moment.

Then he stopped. “Mommy, I don’t feel good.”

Moments later, he began vomiting.

At first, Jenn thought what many parents might think in the middle of travel, work, and a dozen competing responsibilities—of course he gets sick today.

But when the vomiting stopped, something still felt wrong.

Barrett was not responding like himself. He seemed distant and foggy. Disconnected. Jenn and her husband knew this was more than a stomach bug. They rushed him to the emergency room.

After hearing what had happened, the doctor ordered a CT scan. Jenn tried to convince herself it was just caution. Then the doctor came back and told them their son had an abnormality in his brain. An ambulance was already on the way to take Barrett to the children’s hospital.

Jenn wanted so badly to believe everything would be okay. But the fear was already there.

More testing showed that Barrett had an arteriovenous malformation, or AVM, in his brain. He needed surgery as soon as it could be scheduled.

Jenn remembers gripping her husband’s hand and asking the question no parent should ever have to ask: “Doctor, is my son going to die?”

Barrett was four years old.

Thankfully, after a 10-hour craniotomy, Barrett came out of surgery successfully. His family could breathe again—but only for a moment.

After surgery, the neurosurgeon mentioned HHT for the first time and recommended genetic testing for their family, including Barrett’s older sister, Rowan.

That fear came rushing back. Could Rowan have this too? Could Jenn’s husband?

The results confirmed what no family wants to hear: Barrett, Rowan, and Jenn’s husband all have hereditary hemorrhagic telangiectasia.

In one moment, HHT went from something Jenn had never heard of to something that touched the three people she loved most in the world.

More scans and appointments followed.

Rowan was found to have micro-AVMs in her brain, pulmonary AVMs, and concerns involving her liver. Barrett was found to have pulmonary AVMs and later developed two additional brain AVMs that required gamma knife treatment. Jenn’s husband, remarkably, had no detectable AVMs anywhere in his body.

That is one of the hardest parts of HHT. Even within one family, it can look completely different from person to person.

For one person, it may mean few or no visible symptoms. For another, it may mean serious complications in childhood. For families like the Doughtys, it means learning to live with uncertainty while doing everything possible to stay ahead of the disease.

Today, their family’s life with HHT includes frequent nosebleeds, ongoing monitoring, specialist visits, and more hospital time than any family would ever choose.

Some days, Jenn says, they hold tightly to joy. Other days, they cling to it with only the tips of their fingers. But they keep going. They keep hoping.

They hope for better treatments. They hope for new discoveries. They hope for earlier diagnosis. They hope for a future where HHT is understood sooner, treated better, and no longer discovered through crisis.

During HHT Awareness Month, Cure HHT’s Visible Together campaign is shining a light on the families, patients, caregivers, physicians, and researchers who are working toward that future. Together, we are making the invisible parts of HHT seen. We are raising awareness so more families can find answers sooner. And we are fueling the research and care that can change what comes next.

For Jenn, June 23 will always be more than her birthday. It is a reminder of what her family has survived. It is a day to honor Barrett and Rowan’s courage. And it is a chance to make the same wish, again and again, until it comes true.

That one day, no parent will have to ask if their child is going to die because of HHT.

Your gift to Cure HHT helps bring that day closer.

Together, we are Visible Together.

And together, we can build a future where Jenn’s birthday wish comes true.

This HHT Awareness Month, we are Visible Together because visibility changes what is possible.

Your gift to Cure HHT helps support the education, advocacy, research, and expert care that move this community forward. It helps more providers understand HHT. It helps more patients find answers. It helps build a future where rare disease care is not defined by isolation, but by connection, knowledge, and hope. Thanks to a generous group of donors, a significant portion of gifts made during HHT Awareness Month will be matched.

The post Visible Together: Jenn’s Birthday Wish appeared first on CureHHT.